Loading clinical trials...
Loading clinical trials...
A Randomized, Single-Masked, Active-Controlled Phase 2 Study of the Safety, Tolerability, and Efficacy of Repeated Doses of High-Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration
Conditions
Interventions
aflibercept
High-dose aflibercept
Locations
46
United States
Regeneron Study Site
Phoenix, Arizona, United States
Regeneron Study Site
Sun City, Arizona, United States
Regeneron Study Site
Encino, California, United States
Regeneron Study Site
Fullerton, California, United States
Regeneron Study Site
Mountain View, California, United States
Regeneron Study Site
Palm Desert, California, United States
Start Date
November 4, 2019
Primary Completion Date
May 14, 2021
Completion Date
November 30, 2021
Last Updated
August 14, 2023
NCT06346600
NCT05439629
NCT04847895
Lead Sponsor
Regeneron Pharmaceuticals
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions